AML

Donor-Derived NK Cells Safe and Efficacious in Relapsed and Refractory AML
Donor-Derived NK Cells Safe and Efficacious in Relapsed and Refractory AML 1024 649 Lauren Dembeck

Researchers have used their approach for growing large numbers of NK cells to allow repeated dosing for a more effective and less toxic treatment.   Outcomes for patients with relapsed and refractory acute myeloid leukemia (R/R AML) have not significantly improved over the last 30 years. For example, a recent study of patients treated with…